Key result
tPA suggests reduced mortality compared to streptokinase for acute myocardial infarction.
Why the study?
The GUSTO trial results prompted reevaluation of thrombolytic agent choice due to differences in mortality related to dosing and timing of therapy.
Comparison
tPA versus streptokinase thrombolytic therapy
Design
Letter reporting audit following GUSTO trial
Follow-up
6 months audit period
Authors
Loading...
May prompt formulary preference for tPA over streptokinase in acute MI; leaves open real-world cost-effectiveness and generalizability.
Ben M. Lomaestro (1994) conducted a letter in Acute myocardial infarction. tPA vs. Streptokinase was evaluated on Mortality. An institutional audit of lytic therapy was mandated following the GUSTO trial results, which suggested reduced mortality with tPA compared to streptokinase for acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: